BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Dhangar et al. demonstrated effective treatment with multikinase inhibitor sorafenib combined with azacitidine in a patient with atypical CML presenting with leukocytosis and a sole BCR::FGFR1 rearrangement, after dasatinib proved ineffective [14].